Novartis, GSK and the Mayo Clinic will be attending the Cell Culture World Congress 2016 on 23-24 February at the Sofitel Munich Bauerpost, Munich
The companies will discuss their new manufacturing platforms for CAR-T, cell and gene therapy as well as data for upscaling new therapies for rare diseases and oncology applications to a commercial scale in the public.
Bluebird Bio, Oxford Biomedica, Dimension Therapeutics, the University of Pennsylvania, Généthon, UniQure and others will also be at the congress to discuss the new challenges associated with commercialising and scaling up the manufacture of new cell and gene therapies.
Barbara Thorne, previous executive director of Celladon, will also be discussing how to upscale viral vector for gene therapy at the 2000L scale.
Event organisers, Terrapinn, said that the congress focuses on optimising commercial biomanufacture from beginning to end, not just at the research level and will showcase new technologies such as CRISPR/cas9 gene editing, new methods of quality control and looking at the manufacture of new formats such as CAR-T, Cell and Gene therapies.
To register for the event, click here.
